$CYTK Recent Headlines This tiny biotech company takes

New Post Public Reply Private Reply Replies (0) Message Board

Jan 15, 2015 at 11:49 AM

$CYTK Recent Headlines

This tiny biotech company takes the real ice bucket challenge 9:14 a.m. Sept. 2, 2014 - Michael Brush
Cytokinetics plunges 60% after Lou Gehrig's disease drug fails test 9:26 a.m. April 25, 2014 - Russ Britt
Cytokinetics's massive stock plunge may be premature, analyst says 5:18 p.m. Sept. 3, 2013 - Russ Britt
Cytokinetics shares plummet after heart drug fails to meet primary goal 9:56 a.m. Sept. 3, 2013 - Russ Britt
6 gut checks before the stock market's opening bell 6:57 a.m. Aug. 14, 2013 - Shawn Langlois
7 gut checks before the stock market's opening bell 8:00 a.m. July 24, 2013 - Shawn Langlois
Cytokinetics rallies on study publication 11:31 a.m. Sept. 27, 2011 - Val Brickates Kennedy
Cytokinetics sinks 18% in early trading 10:37 a.m. Aug. 8, 2011 - Val Brickates Kennedy
Drug indexes hug the flat line 10:57 a.m. Dec. 13, 2010 - Val Brickates Kennedy
Drug indexes sluggish; Cytokinetics plunges 10:07 a.m. Dec. 13, 2010 - Val Brickates Kennedy
Cytokinetics shares up 5% 9:34 a.m. Dec. 7, 2010 - Nick Godt
Cytokinetics to begin Phase II testing of ALS drug 9:13 a.m. March 11, 2010 - Val Brickates Kennedy
Drug stocks slump; Sequenom jumps on upgrade 1:50 p.m. May 27, 2009 - Val Brickates Kennedy
Cytokinetics appoints Sabry executive chairman 4:27 p.m. Jan. 22, 2007 - Ruth Mantell
Cytokinetics names James Sabry as executive chairman 4:02 p.m. Jan. 22, 2007 - Katherine Hunt
Cytokinetics names Robert Blum as CEO 4:02 p.m. Jan. 22, 2007 - Katherine Hunt
Stem-cell rally as sector moves broadly higher 4:44 p.m. Jan. 4, 2007 - Val Brickates Kennedy
Wednesday's biggest U.S. stock gainers and decliners 5:55 p.m. Jan. 3, 2007 - MarketWatch
Drug stocks mixed; Cytokinetics soars on Amgen deal 4:40 p.m. Jan. 3, 2007 - Val Brickates Kennedy
Cytokinetics, Amgen ink deal to develop heart-failure drugs 11:33 a.m. Jan. 3, 2007 - Val Brickates Kennedy

Jim Cramer's 'Mad Money' Recap: You'll Make More Money Buying Into Panic 8:23 p.m. Jan. 8, 2015 - TheStreet.com
8 Biotechnology Stocks to Buy Now 2:45 a.m. Jan. 7, 2015 - InvestorPlace.com
Cytokinetics (CYTK) Is Weak On High Volume Today 10:09 a.m. Jan. 2, 2015 - TheStreet.com
Cytokinetics (CYTK) Looks Good: Stock Soars 16.1% - Tale of the Tape 9:25 a.m. Jan. 2, 2015 - Zacks.com
Mid-Afternoon Market Update: U.S. Stocks Turn Red; Tekmira Pharmaceuticals Shares Climb Following Clinical Study Update 1:17 p.m. Dec. 31, 2014 - benzinga.com
Cytokinetics (CYTK) Stock Rises Today After Roth Capital Increases Price Target 11:44 a.m. Dec. 31, 2014 - TheStreet.com
Mid-Day Gainers From New Year's Eve 2014: NephroGenex And Other Biopharma Stocks 11:42 a.m. Dec. 31, 2014 - benzinga.com
Cytokinetics Surges Amid Roth Capital Raising Its Price Target 10:52 a.m. Dec. 31, 2014 - benzinga.com
Kite Pharma Files IND for Non-Hodgkin Lymphoma Drug - Analyst Blog 5:20 p.m. Dec. 29, 2014 - Zacks.com
Seeking Alpha's Biotech Weekly: AbbVie Slaps Gilead, Achillion's 'Nuc' Power, And More 4:00 p.m. Dec. 26, 2014 - Seeking Alpha
Strong On High Volume: Cytokinetics (CYTK) 10:59 a.m. Dec. 26, 2014 - TheStreet.com
Will Cytokinetics (CYTK) Continue to Surge Higher? - Tale of the Tape 9:50 a.m. Dec. 26, 2014 - Zacks.com
Cytokinetics Rises After Extending Astellas Agreement - Analyst Blog 5:10 p.m. Dec. 24, 2014 - Zacks.com
Myriad Genetics' Ovarian Cancer Test Wins FDA Approval - Analyst Blog 2:10 p.m. Dec. 24, 2014 - Zacks.com
Cytokinetics, Incorporated (CYTK) Rises: Stock Jumps 12.6% - Tale of the Tape 9:32 a.m. Dec. 24, 2014 - Zacks.com
Will myRisk Cancer Test Work Wonders for Myriad Genetics? - Analyst Blog 2:30 p.m. Dec. 23, 2014 - Zacks.com
Walgreens Beats Q1 Earnings, Alliance Boots Deal Bears Fruit - Analyst Blog 2:02 p.m. Dec. 23, 2014 - Zacks.com
Cytokinetics, Astellas Continue on Muscle Treatment 9:53 a.m. Dec. 23, 2014 - The Wall Street Journal Interactive Edition
Morning Market Movers 8:54 a.m. Dec. 23, 2014 - benzinga.com
Cytokinetics and Astellas expand partnership 8:28 a.m. Dec. 23, 2014 - Seeking Alpha

Happy New 'Investing' Year: Complementary Reports on Daily Journal, Trina Solar, Cytokinetics, BrainStorm, and Resolute 8:10 a.m. Jan. 2, 2015 - PR Newswire - PRF
Cytokinetics and Astellas Announce Expansion of Collaboration for Development of CK-2127107 in Spinal Muscular Atrophy and Other Neuromuscular Indications 7:30 a.m. Dec. 23, 2014 - Thomson Reuters ONE
Cytokinetics Announces Presentations Relating to Tirasemtiv and Effects on Respiratory Muscle Function at International Symposium on ALS/MND 8:01 a.m. Dec. 5, 2014 - Thomson Reuters ONE
Cytokinetics Announces Presentations Relating to Tirasemtiv at the 25th International Symposium on ALS/MND 4:01 p.m. Dec. 1, 2014 - Thomson Reuters ONE
Cytokinetics to Participate in the 26th Annual Piper Jaffray Healthcare Conference 4:01 p.m. Nov. 26, 2014 - Thomson Reuters ONE
Critical Alerts For Outerwall, Cytokinetics, Union Pacific, Accenture and Monsanto Released By InvestorsObserver 9:31 a.m. Nov. 25, 2014 - PR Newswire - PRF
Cytokinetics' President & CEO Robert Blum Receives 2014 Lou Gehrig Iron Horse Award From ALS Therapy Development Institute 7:31 a.m. Nov. 10, 2014 - Thomson Reuters ONE
Cytokinetics, Incorporated Reports Third Quarter 2014 Financial Results 3:01 p.m. Oct. 30, 2014 - Thomson Reuters ONE
Cytokinetics Provides Development Program Update for Omecamtiv Mecarbil 6:31 a.m. Oct. 27, 2014 - Thomson Reuters ONE
Cytokinetics Provides Development Program Update for Tirasemtiv 6:31 a.m. Oct. 20, 2014 - Thomson Reuters ONE
Cytokinetics to Announce Third Quarter Results on October 30, 2014 4:35 p.m. Oct. 16, 2014 - Thomson Reuters ONE
Cytokinetics Announces Development Program Update for CK-2127107 6:31 a.m. Oct. 13, 2014 - Thomson Reuters ONE
Anacor Pharmaceuticals Appoints Wendell Wierenga to Its Board of Directors 7:30 a.m. Sept. 12, 2014 - BusinessWire - BZX
Cytokinetics to Present at the 34th Annual Canaccord Global Growth Conference 3:01 p.m. Aug. 7, 2014 - Thomson Reuters ONE
Cytokinetics, Incorporated Reports Second Quarter 2014 Financial Results 11:18 p.m. July 30, 2014 - Thomson Reuters ONE
Cytokinetics to Announce Second Quarter Results on July 30, 2014 1:46 a.m. July 17, 2014 - Thomson Reuters ONE
Cytokinetics Announced Additional Results Relating to Tirasemtiv from Pre-Specificed Subgroup Analyses of BENEFIT-ALS 6:31 a.m. July 10, 2014 - Thomson Reuters ONE
Biotech Equities under the Scanner -- Research on Alexion Pharma, InterMune, Cytokinetics, and Biogen Idec 4:55 a.m. July 7, 2014 - PR Newswire - PRF
Cytokinetics Announces Additional Data from BENEFIT-ALS to be Presented at the 13th International Congress on Neuromuscular Diseases 6:32 a.m. July 3, 2014 - Thomson Reuters ONE
Cytokinetics Announces Data Relating to Tirasemtiv Presented at the 2014 Annual Spinal Muscular Atrophy Conference 3:01 p.m. June 13, 2014 - Thomson Reuters ONE

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aurra Markets Wins 'Most Transparent Broker' Award 2026

Spotlight on Transparency in Trading Alright, so Aurra Markets snagged the 'Most Transparent Broker' award at the Money Expo in Mumbai this year. From the greasy streets of trading floors to the polished halls of Jio World Convention Centre, transparency is one of those golden words you hear tossed around, but like finding a needle in a haystack, it’s not always easy to...

LITEON Bets Big on Liquid Cooling with DCX Stake

Liquid Cooling: The AI Data Center Game Changer Alright, here's a twist in the tech saga that even a crusty old trader like me finds intriguing. LITEON (2301.TW) has made a bold move investing in DCX Liquid Cooling Systems with a $176 million deal for 25% equity. We're talking about liquid cooling here—it's the magic ingredient when your AI and HPC data centers start...

Ares Management Heads to Barclays Conference Spotlight

All Eyes on Ares – From the Trading Floor to Barclays Nothing like the crisp snap of traders' attention when big players like Ares Management Corporation (NYSE:ARES) are set to spill some beans at a fancy conference. Come September 16, 2026, Ares' head honcho, Michael Arougheti, will be hitting the stage at the Barclays Global Financial Services Conference. It’s the...

Curaleaf Eyes Growth: Conference Signals Opportunities

Curaleaf's Strategic Move: Getting in Front of Investors Here comes Curaleaf Holdings, stepping into the spotlight with their eye on increasing investor engagement. Announcing their participation in the ATB Cormark Capital Markets 2026 Fall Institutional Investor Conference, the folks at Curaleaf aren't just talking—they're putting their top brass under the lights. You...

Navimow's H5 Pro Mower Marries Tech with Nature Care

Garden Tech Reinvented: Enter the H5 Pro Mower Welcome to the 21st-century garden, where robotic ingenuity meets a genuine regard for nature. Folks, the Navimow H5 Pro just rolled onto the scene and it’s tearing up the old playbook of garden maintenance. It’s like blending Silicon Valley tech with Jane Goodall’s wildlife sensibilities. We're talking zero-edge...

Joseph Spine Opens New Regenerative Therapy Center

Regenerative Medicine: A New Frontier in Spine Care When spine care gets a facelift, you take notice. Joseph Spine Institute, a heavyweight in the spine care game, just threw hat into the regenerative ring. We're talking about using a patient's own cells to mend what's broken—that's advanced. They're launching a Regenerative Therapy Center in Tampa, ready to offer these...

Eosera Defies Odds with Texas-Made Ear Care Dominance

Who would've thought an ear care outfit outta Fort Worth could snag a spot on the Inc. 5000 list for six years running? That's right, eosera® is hanging tough, even while the industry's been in a tailspin and tariffs have been squeezing everyone’s margins. Pushing Through Tough Terrain The ear care sector isn't exactly the first place investors look for a splash,...

Perspecta's Study Reveals Troubling Data Accuracy Gaps

Data Accuracy in Healthcare: A Persistent Problem Just when you think data's about numbers and cold, hard facts, healthcare jolts you awake. Perspecta's fresh insights onto provider data accuracy aren't just a snooze fest of statistics but a genuine wake-up call. This report peels open a can of worms some might prefer to ignore. With only half of provider data accurate,...

Nasdaq Flashes Warning Signs for Scage Future's Compliance

Two Strikes from Nasdaq: A Wake-Up Call? Scage Future's getting a double-shot of reality from Nasdaq after slipping under crucial thresholds. Here's the score: Scage's been dinged on their Market Value of Listed Securities (MVLS) and Market Value of Publicly Held Shares (MVPHS). Over a stretch from mid-July to late August, these benchmarks floundered below the line. The...

Alcatraz AI: A Silent Titan in Data Center Security

Why Alcatraz AI is the Security of Choice Forget flashy press releases and splashy marketing campaigns. Alcatraz AI, a company operating out of the hustle and bustle of Cupertino, has managed to quietly dominate a key sector without many folks being the wiser. What's their claim to fame, you ask? They're the chosen gatekeepers for over half of the hyperscale data centers...